SPAC Buys Longevity In $236.2M Deal Led By 2 Firms
Biopharmaceutical company Longevity and special purpose acquisition company Denali Capital announced on Thursday that they had reached an agreement to combine in a deal valuing Longevity Biomedical Inc. at $236.2 million,...To view the full article, register now.
Already a subscriber? Click here to view full article